Oseltamivir for treatment and prophylaxis of influenza infection (Q56785849)

Europe PubMed Central

title

Oseltamivir for treatment and prophylaxis of influenza infection (English)

0 references

main subject

oseltamivir

1 reference

Expert Opinion on Drug Safety

ChEBI release 2020-05-28

Mark Holodniy

2

0 references

Patricia L Schirmer

series ordinal

1

object named as

Patricia Schirmer

0 references

language of work or name

English

0 references

publication date

9 April 2009

0 references

May 2009

0 references

published in

0 references

volume

8

0 references

issue

3

0 references

page(s)

357-371

0 references

357-71

0 references

cites work

The critically ill avian influenza A (H5N1) patient.

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Safety of neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Human infection with highly pathogenic H5N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Update on avian influenza A (H5N1) virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Current and future antiviral therapy of severe seasonal and avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Comparison of the NOW Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A+B assays, and immunofluorescence with viral culture for the detection of influenza A and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Medical management of influenza infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Antivirals and influenza: frequency of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Seasonal and pandemic influenza: a 2007 update on challenges and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Mutations of neuraminidase implicated in neuraminidase inhibitors resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The war against influenza: discovery and development of sialidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir resistance--disabling our influenza defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Antiviral agents active against influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Probenecid with oseltamivir for human influenza A (H5N1) virus infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Population pharmacokinetics of oseltamivir when coadministered with probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Pharmacokinetics of oseltamivir in young and very elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The metabolism and transplacental transfer of oseltamivir in the ex vivo human model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir and breastfeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Use of oseltamivir during an outbreak of influenza A in a long-term care facility in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Clinical benefits with oseltamivir in treating influenza in adult populations : results of a pooled and subgroup analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The course of fever following influenza virus infection in children treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Detecting human-to-human transmission of avian influenza A (H5N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Reduced sensitivity of influenza A (H5N1) to oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Human disease from influenza A (H5N1), Thailand, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Avian influenza A (H5N1) in 10 patients in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Three Indonesian clusters of H5N1 virus infection in 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Avian influenza A (H5N1) infection in eastern Turkey in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Detection and control of influenza outbreaks in well-vaccinated nursing home populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Influenza-associated central nervous system dysfunction: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Adolescent jump case in Japan associated with influenza but not oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir and delirious behavior in children with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Experience with oseltamivir for infants younger than 1 year old in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Resistance of influenza viruses to neuraminidase inhibitors--a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Fatal oseltamivir-resistant influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Structural studies of the resistance of influenza virus neuramindase to inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

News about influenza B drug resistance that cannot be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Enhancement of activity against influenza viruses by combinations of antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519

Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330902840519